{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T05:30:27Z","timestamp":1772861427724,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Integrated Thinking Research Fund of China International Medical Foundation","award":["20201630"],"award-info":[{"award-number":["20201630"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Levosimendan can improve clinical symptoms and the cardiorenal rescue success rate, and stabilize hemodynamic parameters in individuals suffering from acute decompensated heart failure. In addition, Shenfu injection (SFI) has been shown to protect the ischemic heart and enhance myocardial contractility.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>For this randomized control single-blind study, 101 patients with acute decompensated heart failure (ADHF) were enrolled and randomly assigned to control levosimendan (n\u2009=\u200951) and levosimendan\u2009+\u2009SFI injection (n\u2009=\u200950) groups. Attending physicians were not blinded for which arm the patients were allocated. Blood pressure, heart rate, the electrocardiogram, respiratory rate, fluid intake and urine output were all recorded 2\u00a0h and 24\u00a0h after drug infusions had commenced, and the cardiac index (CI) was monitored by ultrasonic cardiac output monitors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Median blood pressure was markedly increased in the levosimendan\u2009+\u2009SFI group after 2\u00a0h and 24\u00a0h from the initiation of infusions compared to levosimendan administration alone. Brain natriuretic peptide (BNP) concentrations were reduced after administrations of levosimendan\u2009+\u2009SFI or solely levosimendan (both <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Alterations in BNP concentrations were not different in the combination and control groups. No differences were found between the 2 groups in heart rate or severe hypotension, but blood pressure (systolic blood pressure, diastolic blood pressure) and hemodynamic parameters including CI, cardiac output and stroke volume index responded better in the levosimendan\u2009+\u2009SFI group compared to the monotherapy levosimendan group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Levosimendan\u2009+\u2009SFI was superior to treat ADHF patients compared to levosimendan monotherapy and produced significant improvements in hemodynamic parameters especially for ADHF patients with hypotension.<\/jats:p>\n                <jats:p><jats:italic>Trail registration<\/jats:italic> The study was prospectively registered at Chinese Clinical Trial Registry with registration number [ChiCTR2000039385] (10\/25\/2020).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-022-02572-2","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T13:05:19Z","timestamp":1648559119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Use of levosimendan combined with Shenfu injection to treat acute heart failure patients with hypotension: a prospective randomized controlled single-blind study"],"prefix":"10.1186","volume":"22","author":[{"given":"Miaomiao","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianli","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiou","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianzhen","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,29]]},"reference":[{"key":"2572_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2147\/TCRM.S188761","volume":"15","author":"E Pashkovetsky","year":"2019","unstructured":"Pashkovetsky E, Gupta CA, Aronow WS. Use of levosimendan in acute and advanced heart failure: short review on available real-world data. Ther Clin Risk Manag. 2019;15:765\u201372.","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"2572_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/1074248416657612","volume":"22","author":"E Gencer","year":"2017","unstructured":"Gencer E, Do\u011fan V, \u00d6zt\u00fcrk MT, Nadir A, Musmul A, Cavu\u015fo\u011flu Y. Comparison of the effects of levosimendan dobutamine and vasodilator therapy on ongoing myocardial injury in acute decompensated heart failure. J Cardiovasc Pharmacol Ther. 2017;22(2):153\u20138.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"9","key":"2572_CR3","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/0022-2828(95)90009-8","volume":"27","author":"H Haikala","year":"1995","unstructured":"Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Lind\u00e9n IB. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol. 1995;27(9):1859\u201366.","journal-title":"J Mol Cell Cardiol"},{"key":"2572_CR4","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ijcard.2016.05.009","volume":"218","author":"MS Nieminen","year":"2016","unstructured":"Nieminen MS, Buerke M, Cohen-Sol\u00e1l A, Costa S, \u00c9des I, Erlikh A, et al. The role of levosimendan in acute heart failure complicating acute coronary syndrome: a review and expert consensus opinion. Int J Cardiol. 2016;218:150\u20137.","journal-title":"Int J Cardiol"},{"issue":"3","key":"2572_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1023\/A:1007878523663","volume":"14","author":"A Lochner","year":"2000","unstructured":"Lochner A, Colesky F, Genade S. Effect of a calcium-sensitizing agent, levosimendan, on the postcardioplegic inotropic response of the myocardium. Cardiovasc Drugs Ther. 2000;14(3):271\u201381.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"6","key":"2572_CR6","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0735-1097(00)00961-X","volume":"36","author":"MS Nieminen","year":"2000","unstructured":"Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000;36(6):1903\u201312.","journal-title":"J Am Coll Cardiol"},{"issue":"27","key":"2572_CR7","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129\u2013200.","journal-title":"Eur Heart J"},{"key":"2572_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.chroma.2015.06.041","volume":"1407","author":"Y Song","year":"2015","unstructured":"Song Y, Zhang N, Shi S, Li J, Zhang Q, Zhao Y, et al. Large-scale qualitative and quantitative characterization of components in Shenfu injection by integrating hydrophilic interaction chromatography, reversed phase liquid chromatography, and tandem mass spectrometry. J Chromatogr A. 2015;1407:106\u201318.","journal-title":"J Chromatogr A"},{"key":"2572_CR9","first-page":"1247","volume":"8","author":"Q Li","year":"2008","unstructured":"Li Q, Li B-Z, Liu H. Pharmacological action and clinical application of Shen Fu injection. Med Recapitul. 2008;8:1247\u201350.","journal-title":"Med Recapitul"},{"issue":"3","key":"2572_CR10","doi-asserted-by":"publisher","first-page":"276","DOI":"10.4103\/wjtcm.wjtcm_45_20","volume":"6","author":"J-G Lin","year":"2020","unstructured":"Lin J-G, Lyu J, Sun M-H, Liao X, Xie Y-M. Systematic review and meta-analysis of shenfu injection on treating acute exacerbation of chronic obstructive pulmonary disease. World J Tradit Chin Med. 2020;6(3):276\u201383.","journal-title":"World J Tradit Chin Med"},{"issue":"5","key":"2572_CR11","first-page":"659","volume":"17","author":"H Qin","year":"2010","unstructured":"Qin H, Liu G, Zhang F, Shen J, Sun H. Clinical observation on Shenfu Zhusheye in the treatment of patients with acute exacerbation chronic obstructive pulmonary disease. Chin J Clin Med. 2010;17(5):659\u201360.","journal-title":"Chin J Clin Med"},{"issue":"10","key":"2572_CR12","first-page":"87","volume":"42","author":"J Xu","year":"2008","unstructured":"Xu J, Lou H, Lou Y, He W, Xu X, Xu D. Research advance in pharmacological action of \u201cShenfu Injection.\u201d Shanghai J Tradit Chin Med. 2008;42(10):87.","journal-title":"Shanghai J Tradit Chin Med"},{"key":"2572_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jep.2016.01.027","volume":"180","author":"J Wu","year":"2016","unstructured":"Wu J, Li C, Yuan W. Effects of Shenfu injection on macrocirculation and microcirculation during cardiopulmonary resuscitation. J Ethnopharmacol. 2016;180:97\u2013103.","journal-title":"J Ethnopharmacol"},{"key":"2572_CR14","doi-asserted-by":"publisher","first-page":"713149","DOI":"10.1155\/2012\/713149","volume":"2012","author":"S Wen-Ting","year":"2012","unstructured":"Wen-Ting S, Fa-Feng C, Li X, Cheng-Ren L, Jian-Xun L. Chinese medicine shenfu injection for heart failure: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2012;2012:713149.","journal-title":"Evid Based Complement Alternat Med."},{"issue":"5","key":"2572_CR15","first-page":"510","volume":"24","author":"J Zhao","year":"2010","unstructured":"Zhao J, Liu J. Clinical application of Shenfu Injection. Chin Pharm Affairs. 2010;24(5):510\u20133.","journal-title":"Chin Pharm Affairs"},{"issue":"1","key":"2572_CR16","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3329\/bjp.v11i1.25124","volume":"11","author":"Y Jiang","year":"2016","unstructured":"Jiang Y, Zhang R-R, Yang L-J, Wu Z, Chen H-P, Tian Z-F. Shenfu injection provides protection for perinatal asphyxia in neonates. Bangladesh J Pharmacol. 2016;11(1):236\u20139.","journal-title":"Bangladesh J Pharmacol"},{"issue":"3","key":"2572_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jgr.2014.03.001","volume":"38","author":"CH Lee","year":"2014","unstructured":"Lee CH, Kim JH. A review on the medicinal potentials of ginseng and ginsenosides on cardiovascular diseases. J Ginseng Res. 2014;38(3):161\u20136.","journal-title":"J Ginseng Res"},{"key":"2572_CR18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jep.2016.12.033","volume":"196","author":"N Zhang","year":"2017","unstructured":"Zhang N, Lian Z, Peng X, Li Z, Zhu H. Applications of Higenamine in pharmacology and medicine. J Ethnopharmacol. 2017;196:242\u201352.","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"2572_CR19","first-page":"75","volume":"23","author":"L Zhang","year":"2011","unstructured":"Zhang L. Curative effect of Shenfu injection on chronic heart failure. Med J West China. 2011;23(1):75\u20136.","journal-title":"Med J West China"},{"key":"2572_CR20","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.3389\/fphar.2019.01424","volume":"10","author":"H Wu","year":"2019","unstructured":"Wu H, Dai Z, Liu X, Lin M, Gao Z, Tian F, et al. Pharmacodynamic evaluation of Shenfu injection in rats with ischemic heart failure and its effect on small molecules using matrix-assisted laser desorption\/ionization-mass spectrometry imaging. Front Pharmacol. 2019;10:1424.","journal-title":"Front Pharmacol"},{"issue":"3","key":"2572_CR21","doi-asserted-by":"publisher","first-page":"e92415","DOI":"10.1371\/journal.pone.0092415","volume":"9","author":"YH Li","year":"2014","unstructured":"Li YH, Yu B, Duan ZZ, Akinyi OM, Yu JH, Zhou K, et al. The coronary dilation effect of Shen Fu injection was mediated through NO. PLoS ONE. 2014;9(3):e92415.","journal-title":"PLoS ONE"},{"key":"2572_CR22","unstructured":"[Chinese guidelines for the diagnosis and treatment of heart failure 2018]. Zhonghua Xin Xue Guan Bing Za Zhi. 2018;46(10):760\u201389."},{"issue":"5","key":"2572_CR23","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s11897-017-0351-y","volume":"14","author":"S Kurmani","year":"2017","unstructured":"Kurmani S, Squire I. Acute heart failure: definition, classification and epidemiology. Curr Heart Fail Rep. 2017;14(5):385\u201392.","journal-title":"Curr Heart Fail Rep"},{"issue":"10","key":"2572_CR24","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.7150\/ijms.6809","volume":"10","author":"F Yuan","year":"2013","unstructured":"Yuan F, Zhao L, Wang J, Zhang W, Li X, Qiu XB, et al. PITX2c loss-of-function mutations responsible for congenital atrial septal defects. Int J Med Sci. 2013;10(10):1422\u20139.","journal-title":"Int J Med Sci"},{"issue":"4","key":"2572_CR25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1177\/1074248415616189","volume":"21","author":"W Wang","year":"2016","unstructured":"Wang W, Liu H, Song M, Fang W, Yuan F. Clinical effect of cardiac shock wave therapy on myocardial ischemia in patients with ischemic heart failure. J Cardiovasc Pharmacol Ther. 2016;21(4):381\u20137.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"2","key":"2572_CR26","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3892\/ijmm.2014.2029","volume":"35","author":"F Yuan","year":"2015","unstructured":"Yuan F, Qiu XB, Li RG, Qu XK, Wang J, Xu YJ, et al. A novel NKX2-5 loss-of-function mutation predisposes to familial dilated cardiomyopathy and arrhythmias. Int J Mol Med. 2015;35(2):478\u201386.","journal-title":"Int J Mol Med"},{"issue":"4","key":"2572_CR27","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/ejhf.1630","volume":"22","author":"L Li","year":"2020","unstructured":"Li L, Liu R, Jiang C, Du X, Huffman MD, Lam CSP, et al. Assessing the evidence-practice gap for heart failure in China: the Heart Failure Registry of Patient Outcomes (HERO) study design and baseline characteristics. Eur J Heart Fail. 2020;22(4):646\u201360.","journal-title":"Eur J Heart Fail"},{"key":"2572_CR28","unstructured":"Lu Y, Zhang Y, Yan Y. Effect of levosimendan on the levels of NT-proBNP and inflammatory markers in patients with acute heart failure. J Hainan Med Univ 2013;19(11):1515\u20137,20."},{"key":"2572_CR29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jep.2019.01.008","volume":"234","author":"X Liu","year":"2019","unstructured":"Liu X, Liu R, Dai Z, Wu H, Lin M, Tian F, et al. Effect of Shenfu injection on lipopolysaccharide (LPS)-induced septic shock in rabbits. J Ethnopharmacol. 2019;234:36\u201343.","journal-title":"J Ethnopharmacol"},{"issue":"11","key":"2572_CR30","first-page":"2972","volume":"27","author":"S Zheng","year":"2012","unstructured":"Zheng S, Wu H, Yu S, Duo W, Ren J, Wang S, et al. Intervention study of Shenfu Injection on cardiomyocyte apoptosis in experimental heart failure rats. China J Tradit Chin Med Pharm. 2012;27(11):2972\u20135.","journal-title":"China J Tradit Chin Med Pharm"},{"issue":"2","key":"2572_CR31","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000357864","volume":"128","author":"Z Jia","year":"2014","unstructured":"Jia Z, Guo M, Zhang YQ, Liang HQ, Zhang LY, Song Y. Efficacy of intravenous levosimendan in patients with heart failure complicated by acute myocardial infarction. Cardiology. 2014;128(2):195\u2013201.","journal-title":"Cardiology"},{"issue":"2","key":"2572_CR32","first-page":"143","volume":"28","author":"J Silva-Cardoso","year":"2009","unstructured":"Silva-Cardoso J, Ferreira J, Oliveira-Soares A, Martins-de-Campos J, Fonseca C, Lousada N, et al. Effectiveness and safety of levosimendan in clinical practice. Rev Port Cardiol. 2009;28(2):143\u201354.","journal-title":"Rev Port Cardiol"},{"issue":"5","key":"2572_CR33","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/MAJ.0000000000000461","volume":"349","author":"Z Jia","year":"2015","unstructured":"Jia Z, Guo M, Zhang LY, Zhang YQ, Liang HQ, Song Y. Levosimendan and nesiritide as a combination therapy in patients with acute heart failure. Am J Med Sci. 2015;349(5):398\u2013405.","journal-title":"Am J Med Sci"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02572-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-022-02572-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02572-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T13:09:27Z","timestamp":1648559367000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-022-02572-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,29]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2572"],"URL":"https:\/\/doi.org\/10.1186\/s12872-022-02572-2","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,29]]},"assertion":[{"value":"9 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study followed the Declaration of Helsinki principles and was approved by the Institutional Review Board of Tongren Hospital affiliated to Shanghai Jiao Tong University School of Medicine. All enrolled patients provided informed consent. The registered trial number was ChiCTR2000039385.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"130"}}